Neurotoxicity testing for regulatory purposes is partly based on in vivo animal studies, which do not include PD-specific behaviour tests48,49, nor PD-related neuropathology studies such as midbrain dopaminergic cell counts or α-synuclein histology10. The gene discussed is SNCA; the disease is Parkinson disease.